Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: Two years' follow-up by high-resolution noninvasive magnetic resonance imaging

Circulation

Volumn 106, Issue 23, 2002, Pages 2884-2887

  Corti, Roberto ^a   Fuster, Valentin ^a   Fayad, Zahi A ^a   Worthley, Stephen G ^a   Helft, Gerard ^a   Smith, Donald ^a   Weinberger, Jesse ^a   Wentzel, Jolanda ^a   Mizsei, Gabor ^a   Mercuri, Michele ^b   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atherosclerosis; Lipids; Magnetic resonance imaging; Plaque

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; AORTA, THORACIC; ARTERIOSCLEROSIS; CAROTID ARTERIES; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SIMVASTATIN; TIME; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 0037016049     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000041255.88750.F0     Document Type: Article

References (18)

1. Vaughan CJ, Gotto AM, Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1-10.
2. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103:276-283.
3. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation. 2001;103:926-933.
4. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: A case-control study. Arterioscler Thromb Vasc Biol. 2001;21:1623-1629.
5. Skinner MP, Yuan C, Mitsumori L, et al. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nature Medicine. 1995;1:69-73.
6. Fayad ZA, Fallon JT, Shinnar M, et al. Noninvasive in vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation. 1998;98:1541-1547.
7. McConnell MV, Aikawa M, Maier SE, et al. MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. Arterioscler Thromb Vasc Biol. 1999;19:1956-1959.
8. Helft G, Worthley SG, Fuster V, et al. Progression and regression of atherosclerotic lesions: Monitoring with serial noninvasive magnetic resonance imaging. Circulation. 2002;105:993-998.
9. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104:249-252.
10. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
11. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
12. Gotto AM, Jr. Statin therapy: Where are we? Where do we go next? Am J Cardiol. 2001;87:13B-18B.
13. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet. 2001;357:577-581.
14. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
15. Moreno PR, Purushothaman KR, Fuster V, et al. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: Implications for plaque vulnerability. Circulation. 2002;105:2504-2511.
16. Michel JB. Contrasting outcomes of atheroma evolution: Intimal accumulation versus medial destruction. Arterioscler Thromb Vasc Biol. 2001;21:1389-1392.
17. Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103:415-422.
18. Tempany CM, McNeil BJ. Advances in biomedical imaging. JAMA. 2001;285:562-567.